Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 31, 2011

Premium

AVI BioPharma, a developer of RNA-based medicines, has named Peter Linsley as its CSO.

Linsley previously served as CSO of Regulus Therapeutics. Prior to that, he was executive director of cancer biology at Merck Research Laboratories.


Rosetta Genomics said that Kenneth Berlin, the firm's president and CEO, has stepped down from its board.

Berlin, who is replaced by board observer Brian Markison, stepped down in observance of good corporate governance practices pursuant to recommendations recently set forth in updated Israeli corporate law, the Rehovot, Israel-based company said.

His role as president and CEO is not affected.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.